The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Open accessAbstract
BACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS: We conducted a double-blind, randomized, placebo-controlled, multicenter, phase 3 trial. Patients received either placebo or eculizumab intravenously; eculizumab was given at a dose of 600 mg weekly for 4 weeks, followed 1 week later by a 900-mg dose and then 900 mg every other week through week 26. The two primary end points were the stabilization of hemoglobin levels and the number of units of packed red cells transfused. Biochemical indicators of intravascular hemolysis and the patients' quality of life were also assessed. RESULTS: Eighty-seven patients underwent randomization. Stabilization of hemoglobin levels in the absence of transfusions was achieved in 49% (21 of 43) of the patients assigned to eculizumab and none (0 of 44) of those assigned to placebo (P<0.001). During the study, a median of 0 units of packed red cells was administered in the eculizumab group, as compared with 10 units in the placebo group (P<0.001). Eculizumab reduced intravascular hemolysis, as shown by the 85.8% lower median area under the curve for lactate dehydrogenase plotted against time (in days) in the eculizumab group, as compared with the placebo group (58,587 vs. 411,822 U per liter; P<0.001). Clinically significant improvements were also found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument (P<0.001) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Of the 87 patients, 4 in the eculizumab group and 9 in the placebo group had serious adverse events, none of which were considered to be treatment-related; all these patients recovered without sequelae. CONCLUSIONS: Eculizumab is an effective therapy for PNH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,018
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Self-citationTakeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Fatigue in cancer patients compared with fatigue in the general United States population
Cella, D., Lai, J., Chang, C., Peterman, A., & Slavin, M. (2002) · Cancer · doi:10.1002/cncr.10245 · Cited by 841
Cella, D., Eton, D. T., Lai, J.-S., Peterman, A. H., & Merkel, D. E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00529-8 · Cited by 808
Diagnosis and management of paroxysmal nocturnal hemoglobinuria
Parker, C. (2005) · Blood · doi:10.1182/blood-2005-04-1717 · Cited by 783
Hillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031688 · Cited by 635
Self-citationRollins, S. A., & Sims, P. J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.9.3478 · Cited by 405
Self-citationHolguin, M. H., Fredrick, L. R., Bernshaw, N. J., Wilcox, L. A., & Parker, C. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114172 · Cited by 403
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Self-citationComplement System Part II: Role in Immunity
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00257 · Cited by 1,051
Howard, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Brodsky, R. A., Young, N. S., Antonioli, E., Risitano, A. M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C.-L., et al. (2008) · Blood · doi:10.1182/blood-2007-06-094136 · Cited by 652
Self-citationParoxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2014) · Blood · doi:10.1182/blood-2014-02-522128 · Cited by 648
Self-citationComplement and coagulation: strangers or partners in crime?
Markiewski, M. M., Nilsson, B., Nilsson Ekdahl, K., Mollnes, T. E., & Lambris, J. D. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.02.006 · Cited by 645
A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics
Mutua, V., & Gershwin, L. J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08804-7 · Cited by 639
Innate immunity in diabetic kidney disease
Tang, S. C. W., & Yiu, W. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0234-4 · Cited by 596
Hillmen, P., Muus, P., Dührsen, U., Risitano, A. M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R. A., Hill, A., et al. (2007) · Blood · doi:10.1182/blood-2007-06-095646 · Cited by 579
Self-citationStegall, M. D., Diwan, T., Raghavaiah, S., Cornell, L. D., Burns, J., Dean, P. G., Cosio, F. G., Gandhi, M. J., Kremers, W., & Gloor, J. M. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03757.x · Cited by 577
Guidelines for the diagnosis and management of aplastic anaemia
Marsh, J. C. W., Ball, S. E., Cavenagh, J., Darbyshire, P., Dokal, I., Gordon‐Smith, E. C., Keidan, J., Laurie, A., Martin, A., Mercieca, J., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07842.x · Cited by 560
Kelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Cohen, D. R., Gregory, W. M., & Hillmen, P. (2011) · Blood · doi:10.1182/blood-2011-02-333997 · Cited by 526
Self-citationUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Thrombosis in paroxysmal nocturnal hemoglobinuria
Hill, A., Kelly, R. J., & Hillmen, P. (2013) · Blood · doi:10.1182/blood-2012-09-311381 · Cited by 478
Self-citationParoxysmal nocturnal haemoglobinuria
Hill, A., DeZern, A. E., Kinoshita, T., & Brodsky, R. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.28 · Cited by 448
Self-citationFirst clinical-grade porcine kidney xenotransplant using a human decedent model
Porrett, P. M., Orandi, B. J., Kumar, V., Houp, J., Anderson, D., Cozette Killian, A., Hauptfeld-Dolejsek, V., Martin, D. E., Macedon, S., Budd, N., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.16930 · Cited by 417
Genetic Variants in C5 and Poor Response to Eculizumab
Nishimura, J.-I., Yamamoto, M., Hayashi, S., Ohyashiki, K., Ando, K., Brodsky, A. L., Noji, H., Kitamura, K., Eto, T., Takahashi, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311084 · Cited by 417
Lee, J. W., Sicre de Fontbrune, F., Wong Lee Lee, L., Pessoa, V., Gualandro, S., Füreder, W., Ptushkin, V., Rottinghaus, S. T., Volles, L., Shafner, L., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876136 · Cited by 416
Self-citationBorowitz, M. J., Craig, F. E., DiGiuseppe, J. A., Illingworth, A. J., Rosse, W., Sutherland, D. R., Wittwer, C. T., & Richards, S. J. (2010) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20525 · Cited by 403
Pittock, S. J., Lennon, V. A., McKeon, A., Mandrekar, J., Weinshenker, B. G., Lucchinetti, C. F., O'Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 395
Hillmen, P., Muus, P., Röth, A., Elebute, M. O., Risitano, A. M., Schrezenmeier, H., Szer, J., Browne, P., Maciejewski, J. P., Schubert, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12347 · Cited by 394
Self-citationKulasekararaj, A. G., Hill, A., Rottinghaus, S. T., Langemeijer, S., Wells, R., Gonzalez-Fernandez, F. A., Gaya, A., Lee, J. W., Gutierrez, E. O., Piatek, C. I., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876805 · Cited by 382
Self-citationParoxysmal nocturnal hemoglobinuria: natural history of disease subcategories
de Latour, R. P., Mary, J. Y., Salanoubat, C., Terriou, L., Etienne, G., Mohty, M., Roth, S., de Guibert, S., Maury, S., Cahn, J. Y., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133918 · Cited by 378
Self-citationColvin, M. M., Cook, J. L., Chang, P., Francis, G., Hsu, D. T., Kiernan, M. S., Kobashigawa, J. A., Lindenfeld, J., Masri, S. C., Miller, D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000093 · Cited by 376
Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Alfinito, F., Camera, A., Gianfaldoni, G., et al. (2009) · Blood · doi:10.1182/blood-2008-11-189944 · Cited by 361
Self-citationClinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Gale, D. P., de Jorge, E. G., Cook, H. T., Martinez-Barricarte, R., Hadjisavvas, A., McLean, A. G., Pusey, C. D., Pierides, A., Kyriacou, K., Athanasiou, Y., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60670-8 · Cited by 327
Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Locke, J. E., Magro, C. M., Singer, A. L., Segev, D. L., Haas, M., Hillel, A. T., King, K. E., Kraus, E., Lees, L. M., Melacon, J. K., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02451.x · Cited by 319
Menne, J., Nitschke, M., Stingele, R., Abu-Tair, M., Beneke, J., Bramstedt, J., Bremer, J. P., Brunkhorst, R., Busch, V., Dengler, R., et al. (2012) · BMJ · doi:10.1136/bmj.e4565 · Cited by 309
Yehoshua, Z., Alexandre de Amorim Garcia Filho, C., Nunes, R. P., Gregori, G., Penha, F. M., Moshfeghi, A. A., Zhang, K., Sadda, S., Feuer, W., & Rosenfeld, P. J. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.044 · Cited by 299
Molecules Great and Small: The Complement System
Mathern, D. R., & Heeger, P. S. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06230614 · Cited by 290
Inhibiting the C5–C5a receptor axis
Woodruff, T. M., Nandakumar, K. S., & Tedesco, F. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.014 · Cited by 289
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Kelly, R. J., Höchsmann, B., Szer, J., Kulasekararaj, A., de Guibert, S., Röth, A., Weitz, I. C., Armstrong, E., Risitano, A. M., Patriquin, C. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502950 · Cited by 286
Self-citationCruz, L. J., Tacken, P. J., Fokkink, R., Joosten, B., Stuart, M. C., Albericio, F., Torensma, R., & Figdor, C. G. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.013 · Cited by 281
“Similar antibodies, such as the Eculizumab antibody, which is used as a negative control for hD1 in our studies, are already approved by the FDA for treatment of patients and are currently in use in the clinic [19,20].”
Eculizumab for Congenital Atypical Hemolytic–Uremic Syndrome
Gruppo, R. A., & Rother, R. P. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0809959 · Cited by 275
Self-citationCOVID-19: A review of therapeutic strategies and vaccine candidates
Izda, V., Jeffries, M. A., & Sawalha, A. H. (2021) · Clinical Immunology · doi:10.1016/j.clim.2020.108634 · Cited by 274
Schrezenmeier, H., Muus, P., Socie, G., Szer, J., Urbano-Ispizua, A., Maciejewski, J. P., Brodsky, R. A., Bessler, M., Kanakura, Y., Rosse, W., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.093161 · Cited by 270
Self-citationHow I treat paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2009) · Blood · doi:10.1182/blood-2009-03-195966 · Cited by 263
Self-citationLong‐term safety and efficacy of eculizumab in generalized myasthenia gravis
Muppidi, S., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2019) · Muscle & Nerve · doi:10.1002/mus.26447 · Cited by 262
van Vliet, E. A., Aronica, E., Vezzani, A., & Ravizza, T. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12444 · Cited by 259
Affibody molecules as engineered protein drugs
Frejd, F. Y., & Kim, K.-T. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.35 · Cited by 225
Ehrnthaller, C., Ignatius, A., Gebhard, F., & Huber-Lang, M. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00149 · Cited by 226
Developing a Valid Patient-Reported Outcome Measure
Rothrock, N. E., Kaiser, K. A., & Cella, D. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.195 · Cited by 222
Diseases of complement dysregulation-an overview
Wong, E. K. S., & Kavanagh, D. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0663-8 · Cited by 115
Risitano, A. M., Röth, A., Soret, J., Frieri, C., de Fontbrune, F. S., Marano, L., Alashkar, F., Benajiba, L., Marotta, S., Rozenberg, I., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00028-4 · Cited by 110
Self-citationThe challenges and promise of complement therapeutics for ocular diseases
Park, D. H., Connor, K. M., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01007 · Cited by 108
Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease
Pierson, S. K., Stonestrom, A. J., Shilling, D., Ruth, J., Nabel, C. S., Singh, A., Ren, Y., Stone, K., Li, H., van Rhee, F., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25123 · Cited by 90
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“Prognosis of patients with severe PNH used to be less than five years, but changed radically with the advent of an anti-complement monoclonal antibody that counteracts membrane fragility.(15) Today, PNH patients treated with this antibody have a normal life expectancy.”
BackgroundConroy, A., Serghides, L., Finney, C., Owino, S. O., Kumar, S., Gowda, D. C., Liles, W. C., Moore, J. M., & Kain, K. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004953 · Cited by 81
C5a anaphylatoxin and its role in critical illness-induced organ dysfunction
Wood, A. J. T., Vassallo, A., Summers, C., Chilvers, E. R., & Conway‐Morris, A. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13028 · Cited by 45
“Blockade of C5 in this way reduces complement‐mediated intravascular haemolysis, which is the hallmark of paroxysmal nocturnal haemoglobinuria (PNH), the disease for which eculizumab is licenced.(114) However, the increased susceptibility of patients treated with eculizumab to Neissieria spp infection (likely due to i…”
BackgroundKusakabe, J., Hata, K., Miyauchi, H., Tajima, T., Wang, Y., Tamaki, I., Kawasoe, J., Okamura, Y., Zhao, X., Okamoto, T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.001 · Cited by 18
Metadata
- Authors
- Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., Browne, P., Risitano, A. M., Hill, A., Schrezenmeier, H., Fu, C.-L., Maciejewski, J., Rollins, S. A., Mojcik, C. F., Rother, R. P., & Luzzatto, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-21
- Volume
- 355
- Issue
- 12
- Pages
- 1233-1243
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2023377972
- Cited by
- 1,303
- References
- 18
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.